Advertisement

ADVERTISEMENT

prostate cancer

Dr
Interview
Dr Schweizer Talks Concordance of DDR Mutations in Paired Primary, Metastatic Prostate Cancer Samples
06/15/2021
Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Michael Schweizer, MD, Seattle...
06/15/2021
Oncology
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways
Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care
Videos
Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care
03/18/2021
03/18/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Videos
Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
02/25/2021
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men with metastatic castration-resistant prostate cancer who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Stephen Freedland, MD, discusses...
02/25/2021
Journal of Clinical Pathways
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
02/23/2021
02/23/2021
Journal of Clinical Pathways
Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists
Videos
Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists
02/21/2021
02/21/2021
Journal of Clinical Pathways
Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC
Videos
Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC
02/21/2021
02/21/2021
Journal of Clinical Pathways
Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials
Videos
Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials
02/19/2021
02/19/2021
Journal of Clinical Pathways
Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost
Videos
Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost
02/19/2021
02/19/2021
Journal of Clinical Pathways
Reductions in PSA Screening Associated With Increased Incidence of Prostate Cancer in US
Videos
Reductions in PSA Screening Associated With Increased Incidence of Prostate Cancer in US
02/19/2021
02/19/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use